BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36208510)

  • 1. A synthetic bivalent peptide ligand of EphB4 with potent agonistic activity.
    Fan T; Liang B; Nie L; Wang J; Zhang H; Ciechanover A; Xu Y; An J; Huang Z
    Eur J Med Chem; 2022 Dec; 244():114804. PubMed ID: 36208510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
    Xiong C; Wen Y; Zhao J; Yin D; Xu L; Chelariu-Raicu A; Yao C; Leng X; Liu J; Chaudhari RR; Zhang S; Sood AK; Li C
    Sci Rep; 2020 Jan; 10(1):520. PubMed ID: 31949258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
    Noberini R; Mitra S; Salvucci O; Valencia F; Duggineni S; Prigozhina N; Wei K; Tosato G; Huang Z; Pasquale EB
    PLoS One; 2011; 6(12):e28611. PubMed ID: 22194865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
    Duggineni S; Mitra S; Noberini R; Han X; Lin N; Xu Y; Tian W; An J; Pasquale EB; Huang Z
    Biochem Pharmacol; 2013 Feb; 85(4):507-13. PubMed ID: 23253822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy.
    Ehlken C; Martin G; Lange C; Gogaki EG; Fiedler U; Schaffner F; Hansen LL; Augustin HG; Agostini HT
    Acta Ophthalmol; 2011 Feb; 89(1):82-90. PubMed ID: 19764912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
    Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
    Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
    Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation.
    Wang Y; Menendez A; Fong C; ElAlieh HZ; Chang W; Bikle DD
    J Bone Miner Res; 2014 Aug; 29(8):1900-13. PubMed ID: 24677183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ephrin‑B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis‑free survival in breast cancer.
    Magic Z; Sandström J; Perez-Tenorio G
    Int J Oncol; 2019 Dec; 55(6):1275-1286. PubMed ID: 31638179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis.
    Sasine JP; Kozlova NY; Valicente L; Dukov J; Tran DH; Himburg HA; Kumar S; Khorsandi S; Chan A; Grohe S; Li M; Kan J; Sehl ME; Schiller GJ; Reinhardt B; Singh BK; Ho R; Yue P; Pasquale EB; Chute JP
    Cancer Res; 2024 Mar; 84(6):919-934. PubMed ID: 38231476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
    Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM
    Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development.
    Cowan CA; Yokoyama N; Saxena A; Chumley MJ; Silvany RE; Baker LA; Srivastava D; Henkemeyer M
    Dev Biol; 2004 Jul; 271(2):263-71. PubMed ID: 15223333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated EFNB2 and EPHB4 promotes lung development in a nitrofen-induced congenital diaphragmatic hernia rat model.
    Liu H; Li X; Yu WQ; Liu CX
    Int J Mol Med; 2018 Nov; 42(5):2373-2382. PubMed ID: 30106123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
    Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity.
    Chrencik JE; Brooun A; Recht MI; Kraus ML; Koolpe M; Kolatkar AR; Bruce RH; Martiny-Baron G; Widmer H; Pasquale EB; Kuhn P
    Structure; 2006 Feb; 14(2):321-30. PubMed ID: 16472751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic changes occur in patterns of endometrial EFNB2/EPHB4 expression during the period of spiral arterial modification in mice.
    Zhang J; Dong H; Wang B; Zhu S; Croy BA
    Biol Reprod; 2008 Sep; 79(3):450-8. PubMed ID: 18463357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
    Xiong C; Huang M; Zhang R; Song S; Lu W; Flores L; Gelovani J; Li C
    J Nucl Med; 2011 Feb; 52(2):241-8. PubMed ID: 21233177
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.